

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Application Number</b>	10/529,097	
			<b>Filing Date</b>	September 24, 2003 (Int'l)	
			<b>First Named Inventor</b>	Ernest ARENAS	
			<b>Art Unit</b>	1632	
			<b>Examiner Name</b>	J. Hama	
<b>Sheet</b>	1	of	3	<b>Attorney Docket Number</b>	441472001300

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2002/0114788-A1	08-22-2002	Isacson et al.	
	2.	US-6,312,949-B1	11-06-2001	Sakurada et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	3.	WO-96/09543-A1	03-28-1996	Neurospheres Ltd.	
	4.	WO-96/15224-A1	05-23-1996	Neurospheres Holding Ltd.	
	5.	WO-02/09733-A1	02-07-2002	The McLean Hospital Corporation	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 9). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	6.	ÅKERUD, P. et al. (October 15, 2001). "Neuroprotection Through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson's Disease," <i>J. Neurosci.</i> 21(20):8108-8118.			
	7.	ÅKERUD, P. et al. (2002). "Persephin-overexpressing Neural Stem Cells Regulate the Function of Nigral Dopaminergic Neurons and Prevent Their Degeneration in a Model of Parkinson's Disease," <i>Mol. Cell. Neurosci.</i> 21:205-222.			
	8.	ARENAS, E. et al. (1998). "Nurr1 Overexpression Enriches for Neuronal Phenotype in Multipotent, Neural Stem-Like," <i>28th Annual Meeting of the Society for Neuroscience</i> , Los Angeles, CA, November 7-12, 1998, 24:1531, Abstract No. 606.10.			
	9.	BJÖRKLUND, A. et al. (July 2003). "Neural Transplantation for the Treatment of Parkinson's Disease," <i>Lancet Neurol.</i> 2(7):437-445.			
	10.	COCHEN, V. et al. (August 2003). "Transplantation in Parkinson's Disease: PET Changes Correlate With the Amount of Grafted Tissue," <i>Mov. Disord.</i> 18(8):928-932.			
	11.	DENIS-DONINI, S. et al. (February 16, 1984). "Glial Heterogeneity may Define the Three-dimensional Shape of Mouse Mesencephalic Dopaminergic Neurons," <i>Nature</i> 307:641-643.			
	12.	DUNNETT, S.B. et al. (May 2001). "Cell Therapy in Parkinson's Disease - Stop or Go?," <i>Nat. Rev. Neurosci.</i> 2(5):365-369.			

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/529,097
		<b>Filing Date</b>	September 24, 2003 (Int'l)
		<b>First Named Inventor</b>	Ernest ARENAS
		<b>Art Unit</b>	1632
		<b>Examiner Name</b>	J. Hama
<b>Sheet</b>	2	of	3
		<b>Attorney Docket Number</b>	441472001300

13.	FOX, J.L. (February 2000). "Gene Therapy Clinical Trials Raise Troubling Questions," <i>ASM News</i> 66(2):1-3.	
14.	FREED, C.R. et al. (October 2003). "Do Patients With Parkinson's Disease Benefit From Embryonic Dopamine Cell Transplantation," <i>J. Neurol.</i> 250(Suppl. 3):II/44-46.	
15.	GERLACH, M. et al. (October 2002). "Current State of Stem Cell Research for the Treatment of Parkinson's Disease," <i>J. Neurol.</i> 249(Suppl. 3):III/33-35.	
16.	GILL, S.S. et al. (May 2003; e-pub. March 31, 2003). "Direct Brain Infusion of Glial Cell Line-Derived Neurotrophic Factor in Parkinson Disease," <i>Nat. Med.</i> 9(5):589-595.	
17.	GRITTI, A. et al. (1995). "Basic Fibroblast Growth Factor Supports the Proliferation of Epidermal Growth Factor-Generated Neuronal Precursor Cells of the Adult Mouse CNS," <i>Neurosci. Lett.</i> 185(3):151-154.	
18.	HAGELL, P. et al. (August 2001). "Cell Survival and Clinical Outcome Following Intrastriatal Transplantation in Parkinson Disease," <i>J. Neuropathol. Exp. Neurol.</i> 60(8):741-752.	
19.	HAQUE, N.S.K. et al. (May-June 1997). "Differential Dissection of the Rat E16 Ventral Mesencephalon and Survival and Reinnervation of the 6-OHDA-lesioned Striatum by a Subset of Aldehyde Dehydrogenase-Positive TH Neurons," <i>Cell Trans.</i> 6(3):239-248.	
20.	HSICH, G. et al. (March 20, 2002). "Critical Issues in Gene Therapy for Neurologic Disease," <i>Hum. Gene Ther.</i> 13:579-604.	
21.	KIRIK, D. et al. (February 2004). "Localized Striatal Delivery of GDNF as a Treatment for Parkinson Disease," <i>Nat. Neurosci.</i> 7(2):105-110.	
22.	KORDOWER, J.H. et al. (October 27, 2000). "Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease," <i>Science</i> 290:767-773.	
23.	LUO, D. et al. (January 2000). "Synthetic DNA Delivery Systems," <i>Nat. Biotechnol.</i> 18:33-37.	
24.	PALÚ, G. et al. (1999). "In Pursuit of New Developments for Gene Therapy of Human Diseases," <i>J. Biotechnol.</i> 68:1-13.	
25.	PANCHISION, D.M. et al. (1998). "An Immortalized Type-1 Astrocyte of Mesencephalic Origin; Source of a Dopaminergic Neurotrophic Factor," <i>J. Mol. Neurosci.</i> 11(3):209-221.	
26.	PICCINI, P. et al. (November 2000). "Delayed Recovery of Movement-Related Cortical Function in Parkinson's Disease After Striatal Dopaminergic Grafts," <i>Ann. Neurol.</i> 48(5):689-695.	
27.	SAUCEDO-CARDENAS, O. et al. (March 1998). "Nurr1 is Essential for the Induction of the Dopaminergic Phenotype and the Survival of Ventral Mesencephalic Late Dopaminergic Precursor Neurons," <i>PNAS</i> 95:4013-4018.	
28.	SCHWARZ, J. (December 2003). "Rationale for Dopamine Agonist use as Monotherapy in Parkinson's Disease," <i>Curr. Opin. Neurol.</i> 16(Suppl. 1):S27-S33.	
29.	SONG, H. et al. (May 2, 2002). "Astroglia Induce Neurogenesis From Adult Neural Stem Cells," <i>Nature</i> 417:39-44.	
30.	TAKESHIMA, T. et al. (1994). "Astrocyte-Dependent and -Independent Phases of the Development and Survival of Rat Embryonic Day 14 Mesencephalic Dopaminergic Neurons in Culture," <i>Neuroscience</i> 60(3):809-823.	
31.	TENENBAUM, L. et al. (2002). "Neuroprotective Gene Therapy for Parkinson's Disease," <i>Curr. Gene Ther.</i> 2(4):451-483.	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/529,097		
		Filing Date	September 24, 2003 (Int'l)		
		First Named Inventor	Ernest ARENAS		
		Art Unit	1632		
		Examiner Name	J. Hama		
Sheet	3	of	3	Attorney Docket Number	441472001300

	32.	VERMA, I.M. et al. (September 18, 1997). "Gene Therapy – Promises, Problems, and Prospects," <i>Nature</i> 389:239-242.	
	33.	VON BOHLEN UND HALBACH, O.B. et al. (June 2004). "Genes, Proteins, and Neurotoxins Involved in Parkinson's Disease," <i>Prog. Neurobiol.</i> 73(3):151-177.	
	34.	Non-Final Office Action mailed July 16, 2003, for U.S. Patent Application No. 09/980,913 filed May 21, 2002, nine pages.	
	35.	Non-Final Office Action mailed May 11, 2004, for U.S. Patent Application No. 09/980,913 filed May 21, 2002, 30 pages.	
	36.	Non-Final Office Action mailed July 29, 2005, for U.S. Patent Application No. 09/980,913 filed May 21, 2002, 24 pages.	
	37.	Final Office Action mailed April 19, 2006, for U.S. Patent Application No. 09/980,913 filed May 21, 2002, eight pages.	
	38.	Non-Final Office Action mailed September 5, 2007, for U.S. Patent Application No. 09/980,913 filed May 21, 2002, 17 pages.	
	39.	Final Office Action mailed June 24, 2008, for U.S. Patent Application No. 09/980,913 filed May 21, 2002, seven pages.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.